AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

PURPOSE: Patients with indolent non-Hodgkin lymphoma typically respond well to first-line immunochemotherapy. At relapse, single-agent rituximab is commonly administered. Data suggest the immunomodulatory agent lenalidomide could increase the activity of rituximab. METHODS: A phase III, multicenter,...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Oncol
Päätekijät: Leonard, John P., Trneny, Marek, Izutsu, Koji, Fowler, Nathan H., Hong, Xiaonan, Zhu, Jun, Zhang, Huilai, Offner, Fritz, Scheliga, Adriana, Nowakowski, Grzegorz S., Pinto, Antonio, Re, Francesca, Fogliatto, Laura Maria, Scheinberg, Phillip, Flinn, Ian W., Moreira, Claudia, Cabeçadas, José, Liu, David, Kalambakas, Stacey, Fustier, Pierre, Wu, Chengqing, Gribben, John G.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2019
Aiheet:
ORIGINAL REPORTS
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7035866/
https://ncbi.nlm.nih.gov/pubmed/30897038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00010
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia